cyrilzakka/clinical-trials huggingface dataset:
Opposite SI Joint Stretching for GIRD

The purpose of this study is to investigate if stretching the contralateral sacroiliac (SI) joint improves GIRD in baseball players. Additionally, we aimed to compare our SI joint stretching regiment with a classically described sleeper stretch routine.

Abstract:

Background:

Glenohumeral Internal Rotational Deficit (GIRD) is a well-documented finding in throwing athletes.

Hypothesis/Purpose:

The purpose of this study is to investigate if stretching the contralateral sacroiliac (SI) joint improves GIRD in baseball players. Additionally, the effect of the SI joint stretch will be compared to that of the classically described sleeper stretch.

Study Design:

Randomized Controlled Clinical Trial

Methods:

With the athlete supine and arm abducted 90o, internal rotation of both shoulders was measured in 23 minor league baseball players.

Next, each player randomly was assigned to either a control (sleeper stretch of dominant shoulder) or experimental (stretch of the SI joint contralateral to the dominant shoulder) group supervised by a certified athletic trainer. The players performed their own stretches.

Finally, the initial two investigators, unaware of to which group the player was assigned, re-measured the end-range internal rotation of each athlete's dominant shoulder.

Eligibility Criteria:
Inclusion Criteria:

* All members a minor league baseball team

Exclusion Criteria:

* Any active shoulder or back injury or history of shoulder or back injury
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of COPD with symptoms over 1 year
* FEV1/FVC \< 70% and FEV1 \>= 30 and \< 80 % of predicted post-bronchodilator
* Symptomatic COPD for a total of 7 days in the two weeks prior to randomisation
* At least 1 COPD exacerbation from 4 weeks to 12 months before the screening visit

Exclusion Criteria:

* Past history or current evidence of clinically significant heart disease
* Current diagnosis of asthma
* Patients who require long term oxygen therapy
* Worsening of COPD requiring treatment with antibiotics, an increase in inhaled steroid dose and/or oral steroids within 4 weeks of study visit 1b
Comprehensive Swallowing Rehabilitation in Patients With MSA

The purpose of this study is to investigate the effect of comprehensive swallowing rehabilitation in patients with multiple system atrophy.

Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease characterized by parkinsonism, cerebellar syndrome, and autonomic failure. Dysphagia is a clinically significant symptom leading to pneumonia that causes death in patients with MSA. Although the symptoms of dysphagia in the two subtypes of MSA-the parkinsonian variant and the cerebellar variant- are different, there is no significant difference in the latency to onset of tube feeding. Therefore, effective intervention is needed to improve the safety and efficiency of swallowing regardless of the subtypes of MSA.

Although swallowing rehabilitation has been widely applied for swallowing disorders in patients with MSA, few studies have reported the clinical effect of applying swallowing therapy. Comprehensive swallowing rehabilitation has focused on functional muscle training, compensatory swallowing maneuvers, and thermal-tactile stimulation, which is used to treat dysphagia from stroke, Parkinson's disease, and head and neck cancer. Therefore, this study aims to investigate the effect of comprehensive swallowing rehabilitation in patients with MSA.

Eligibility Criteria:
Inclusion Criteria:

* Age \>19 years
* Clinically diagnosed with MSA according to the guidelines of the 2nd consensus of the Gilman criteria
* Clinically diagnosed to have dysphagia by a physiatrist
* Two or more points on the Penetration-aspiration scale (PAS) from the Videofluoroscopic swallowing study (VFSS) conducted within 3 months

Exclusion Criteria:

* Moderate to severe cognitive dysfunction with Mini-mental State Examination score \< 19
* Comorbidities or structural abnormalities that may affect swallowing function
* Other comorbidities that make it difficult to participate in the study
A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Incomplete Closed Protocol


Eligibility Criteria:
Information not available
Trendelenburg Maneuver Versus Passive Leg Raising Test for Fluid Responsiveness in High-Risk Surgical Patients

The aim of this study is to evaluate whether Trendelenburg maneuver can be used to predict fluid responsiveness in high-risk surgical patients in intensive care unit as compared to Passive Leg Raising test.

Passive Leg Raising test is a well validated dynamic method to predict fluid responsiveness with many advantages as it doesn't use fluid loading, its effect is reversible, and it doesn't rely on heart-lung interaction. However, it has many limitations as (has false negative effect in patients with intra-abdominal hypertension), also, it may not be suitable in some surgical patients.

Trendelenburg maneuver (TM) is often used to treat hemodynamic unstable patients when hypovolemia is suspected, through a mechanism similar to Passive Leg Raising test Yonis, et al reports that change in cardiac output during Trendelenburg maneuver is a reliable predictor of fluid responsiveness in patients with acute respiratory distress syndrome in prone position under protective ventilation. Another study reports that change in velocity time integral during trendelenburg maneuver predicts fluid responsiveness in cardiac surgical patients in operating rooms

Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 18 years old.
* Criteria of high-risk surgical patients:

  1. Elderly ≥ 70 years old undergoing major surgery.
  2. Physical status ≥ 3 or more undergoing major surgery.
  3. Major intraoperative hemorrhage with Surgical Apgar Score (SAS 0-4).
  4. Emergency of upper abdominal surgery.
* Criteria of hypoperfusion ≥ 2 or more the following:

  1. Mean arterial blood pressure \< 65 mmHg.
  2. Urine output \< 0.5 ml/Kg/hr.
  3. Capillary refilling time \> 4 seconds.
  4. Blood lactate \> 2 mmol/L.
  5. ScvO2 \< 70%.
  6. CO2 gap \> 6 mmHg.
* Provided that:SpO2 ≥ 90% and Hb ≥ 7 g/dl.

Exclusion Criteria:

* Patients with body mass index \> 35 kg/m2.
* Pregnant female.
* Contraindications to the Trendelenburg position or PLR test (major head trauma, intra-abdominal hypertension and gastric retention).
* Poor echo window or unsatisfactory cardiac echogenicity (an inability to correctly align the Doppler beam to generate reliable velocity time integral measurements at the left ventricular outflow tract \[LVOT\]).
Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention

Introduction: There are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (QT) or radiotherapy (RT). In this study we will collect the variables referring to oral mucositis (OM), radiodermatitis, osteonecrosis of the jaws (ONJ), hyposalivation and xerostomia, dysgeusia, pain, oral candidiasis (opportunistic infection), trismus, quality of life, oral hygiene.

MO and hyposalivation, which are related to damage to the salivary glands, are the most common manifestations, and ONJ is the most difficult to treat. The dentist can play an important role in prevention and treatment these oral lesions, directly influencing the patient's quality of life and adherence to antineoplastic treatment.

Objectives: The main objective is to evaluate the efficacy of the intervention, using LLL phototherapy and topical Vit E, in the OM. And the intervention through LLL phototherapy and LPRP in the ONJ. These interventions will be performed by dentists during antineoplastic medical treatment.

Material and methods: clinical trial, randomized, with balanced randomization, single-blind (for the evaluator of the results) with 2 experimental arms and a control group, carried out in a single center. Group 1, intervention with LLL phototherapy, Group 2, intervention with application of topical Vit E and Group 3, mouthwash with 0.12% chlorhexidine (usual clinical information). 360 patients will participate in this study from the Units of Oncology Medicine, Radiotetaphic Medicine and Oral Medicine, Oral Surgery and Implantology at the University of Santiago de Compostela. The segment of the patients will be given, an initial visit and returns every day that hears the application of antineoplastic treatment for the group of LLL phototherapy, returns of 15 days, one month, three months, six months, nine months and one year. In these return visits, evaluations and questionnaires will be carried out regarding all the variables that we will collect.

Predictable results: If the application of laser phototherapy or topical Vit E contributes to the cessation, reduction or improvement of the clinical evolution of the manifestation of oral lesions, these treatments could be immediately implemented in our Oral Medicine unit and could lay the foundations for its implementation in different public centers and private.


Eligibility Criteria:
Inclusion Criteria:

* Patients with head and neck or breast cancer who will undergo chemotherapy or radiotherapy.

Exclusion Criteria:

* Participants who do not sign the informed consent.
* Patients who have been or will be treated by chemo and radiotherapy together.
* Patients in treatment of a cancer recurrence.
* Patients reporting diabetes or sjogren's syndrome.
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Primary objective: Evaluation of the safety of Seretide discus administration in subjects with COPD. Treatment duration: 2 years. Study has 3 phases: Screening phase (visit 1), treatment phase (visits 2-5. In the case of AE, there will be another visit (visit 6) as a follow up visit - follow up phase.


Eligibility Criteria:
Inclusion Criteria:

* Subject should fulfill criteria for the subscription of SERETIDE as these are mentioned in SPC.

Exclusion Criteria:

* Hypersensitivity to Salmeterol + Fluticasone or any of its excipients
* Pregnancy, lactation or scheduled pregnancy during the observational period of the study
* Serious illness/disease, not adequately controlled, or with a potential to interfere with the patients' participation in the present study, according to the investigator/physician's judgment.
Qvar Therapy in Smoking Asthmatics

To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone (EF HFA-BDP) and other inhaled corticosteroid (ICS) therapy commonly used in the UK, specifically fluticasone (FP) and non-extrafine (NEF) BDP (CFC-BDP and NEF HFA-BDP) in a UK primary care asthma population of current smokers.


Eligibility Criteria:
Inclusion Criteria:

* Aged 16-70 years
* Current smokers - explicitly coded in patient records or captured in patient questionnaires
* Evidence of asthma diagnosis and current therapy: ≥2 prescriptions for asthma at different points in time during the baseline year ± a diagnostic code for asthma
* On-going asthma therapy: ≥2 prescription for ICS during the outcome period (i.e. ≥1 prescription in addition to IPD prescription)
* ≥2 years continuous data (i.e. ≥1 year of baseline plus ≥1 year of outcome data)

Exclusion Criteria:

Patients will be excluded from the analysis if they have:

* Any chronic respiratory disease other than asthma
* Are prescribed:
* Maintenance oral steroid therapy during the baseline year
* Combination ICS/long-acting beta agonist (LABA) therapy during baseline year or at IPD
* Multiple ICS prescriptions at IPD or immediately before .
Ultrasound Guided Infraclavicular Brachial Plexus Block Using Levo-bupivacaine Alone or Combined With Dexmedetomidine for Hand and Forearm Surgeries

To evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries as regard:

Onset of sensory and motor blockade. Duration of sensory and motor blockade.

Analgesic pain scores using the verbal rating scale (VRS) for pain. Duration of analgesia postoperative complications.

Technique for ultrasound guided infraclavicular brachial plexus block:

Preliminary scan

* The patient is positioned supine with the arm abducted to 90°(or resting by their side if unable to do so).
* The probe is placed immediately medial to the coracoid process in the parasagittal plane.
* Identify the pectoralis major and minor muscles superficially and the axillary artery and vein(s) deep to this. The vein is usually caudad relative to the artery.
* The cords of the brachial plexus are seen as either hypoechoic or hyperechoic structures positioned around the axillary artery. The lateral cord is lateral (cephalad) to the artery, the medial cord medial (caudad),and the posterior cord posterior (deep). They can be difficult to visualize but are usually positioned closely to the artery.

Ultrasound settings

* Probe: high-frequency (\>10MHz) linear broadband probe.
* Settings: MB-resolution/general.
* Depth: 3-6cm.
* Orientation: parasagittal.
* Needle: 50-100mm depending on depth of plexus. Technique
* An in-plane approach is recommended, inserted from the cephalad end of the transducer.
* Needle tip visualization may be challenging as the needle angle can be quite steep.
* Prepare the skin with 0.5% chlorhexidine in 70% alcohol. Wait until the skin is dry.
* Anaesthetize the skin with a subcutaneous injection of 1% lidocaine at the point of needle insertion.
* The needle is first advanced posterolateral to the artery to deposit local anesthetic around the posterior cord, 5 o'clock position on artery.
* After careful aspiration LA is injected in small aliquots, observing the spread of the LA which ideally occurs behind and up both sides of the artery forming a 'U' shape around the artery, 1-9 o'clock around the artery.
* If medial (caudad) spread is not observed then reinsertion of the needle between the axillary artery and vein, adjacent to the medial cord may be required.

Eligibility Criteria:
Inclusion Criteria:

* Age: 20-65 years old.
* American society of anesthesiologist physical status (ASA): I-II.
* Operation: forearm \& hand surgeries.

Exclusion Criteria:

* Patients with chronic pain
* Those using chronic analgesic medications
* History of brachial plexus injury
* Allergy to the study drugs
* Hepatic or renal insufficiency or infection at the site of injection
Sleep Quality in Carpal Tunnel Syndrome, Splinting and Kinesiotaping

The effect of conservative treatments on sleep quality in carpal tunnel syndrome is unclear.

Comparing the effect of splinting and kinesiotaping in carpal tunnel syndrome on functional status, pain, grip strength, nerve cross-sectional area and sleep quality.

Participants were divided into 3 groups. One group received night splint and nerve tendon gliding exercises, one group received kinesiotaping and nerve tendon gliding exercises, and one group received only nerve tendon gliding exercises. Participants were evaluated by a blinded investigator at baseline and at 3 months by Visual Analogue Scale (VAS), Boston Carpal Tunnel Syndrome Questionnaire, Pittsburgh Sleep Quality Index (PSQI), Jamar hand dynamometer and ultrasonography.


Eligibility Criteria:
Inclusion Criteria

* Being diagnosed with mild and moderate carpal tunnel syndrome with nerve conduction velocity study
* To be between the ages of 18-65

Exclusion Criteria:

* Inflammatory disease (rheumatoid arthritis, tendinitis, etc.),
* Osteoarthritis in the hand/wrist,
* Musculoskeletal conditions (hand, elbow, wrist),
* Thyroid disease
* Chronic kidney failure
* Carpal tunnel syndrome surgery,
* History of surgery and/or trauma to the upper extremity and neck.
* Pregnancy or diabetes-related carpal tunnel syndrome,
* Receiving any treatment for carpal tunnel syndrome (splint therapy, electrophysical agents, exercise, local corticosteroid injection) up to 3 months prior to the tests.
Acetazolamide in Patients With Acute Heart Failure

Introduction: Recent studies have suggested that the use of acetazolamide may assist in the vol- ume management of patients with decompensated heart failure (HF). However, prospective and randomized comparison in patients with HF and optimized diuretic therapy has not been described. Objective: The aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated HF. Methodology: For this, a unicentric, randomized, double blind and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose, complications) of patients will be analyzed for safety and effectiveness. Expected results: The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for volume control in patients with decompensated HF.


Eligibility Criteria:
Inclusion Criteria:

* Adult men and women aged\> 18 years.
* Patients with LVEF ≤ 40% documented on echocardiography
* BNP\> 500 pg / mL
* Signed consent form.

Exclusion Criteria:

* Pregnancy
* COPD
* Hepatical cirrhosis
* Known allergy to acetazolamide
* 2nd or 3rd degree atrioventricular block.
* SBP \<90 mmHg or need for vasopressor / inotropic use.
* Body mass index greater than 40 kg / m2.
* Acute coronary syndrome.
* Orotracheal intubation.
* Presence of significant pericardial effusion.
* Left ventricular outflow tract obstruction.
* Serum creatinine\> 5.0 mg / dL, creatinine clearance \<10 mL / min or hemodialysis.
* Presence of 2 or more clinical / laboratory / radiological criteria of infection defined by:

  * Fever
  * Leukocyte\> 12,000 / mm3 or\> 10% of young forms,
  * Disuria
  * Productive cough
  * Bacteremia
  * Inflammatory / infectious skin lesions
  * Abdominal pain with signs of peritonitis
  * Radiological image of pneumonia.
Slow Expansion and Protraction in Cleft Lip and Palate Patients

Evaluate the treatment outcome of slow maxillary expansion protocol on patients with cleft lip and palate, using a differential opening expander and face mask which will be measured and recorded by cone beam computed tomography (CBCT).

Cleft lip and palate are among the most common deformities in children. Cleft patients are usually having orofacial problems as missing or unerupted permanent teeth, alveolar bone defect, speech difficulty. Patients with cleft lip and palate (CLP) commonly have maxillary arch constriction (maxillary hypoplasia) and Class III malocclusions due to deficient of maxillary growth. The upper jaw of patients with cleft palate will be expanded using maxillary Expander with Differential Opening (EDO) which has two screws; one anterior and one posterior. This will be done with slow expansion protocol, which is one 1/4 turn three times weekly. Petit facemask will be used to protract the retracted maxilla. The differences in measurements between before and after treatment will be assessed by cone beam computed tomography (CBCT).

Eligibility Criteria:
Inclusion Criteria:

* All patient age ranges from 8 to 12 years.
* Patients of both sexes.
* Cleft lip and palate patients.
* All the cases showed maxillary arch constriction and deficiency.
* All patients had maxillary permanent first molars.
* Primary lip adhesion and palatal closure.

Exclusion Criteria:

* Patients had received any surgical assisted rapid maxillary expansion or maxillary protraction of fixed orthodontics before.
* Maxillary dentition unsuitable to bond the expander (less than two dental units beside permanent first molar).
* Absent maxillary permanent first molars.
* Uncooperative patients/parents.
MI-BP: mHealth to Improve Blood Pressure Control

This study seeks to evaluate a multicomponent mobile intervention to change multiple hypertension-related health behaviors in minorities and the underserved with uncontrolled hypertension. Half of the participants will receive a mobile intervention designed to improve physical activity, sodium intake, and medication adherence. The other half will receive usual care.


Eligibility Criteria:
Inclusion Criteria:

* Detroit-area residents
* Hypertensive
* Owning a compatible smartphone
* Presenting to the Detroit Medical Center Detroit Receiving, Sinai-Grace Hospital, or selected Community Health Screening Events with, but not necessarily for, uncontrolled blood pressure (systolic blood pressure ≥ 135 mm Hg at triage and on repeat measurement using the BpTRU device).

Exclusion Criteria:

* No self-reported prior history of hypertension
* No hypertension diagnosis documented in their medical record
* Non-English speaking
* Presenting with an acute illness necessitating immediate medical intervention
* Presenting with an admission to the hospital for critical reasons (as determined by the attending physician)
* Pregnant (as determined by a dip test at screening), or self-report during trial.
* Having the following serious comorbidities or confounders due to the fact that they may make blood pressure control difficult or necessitate frequent Emergency Department use or hospitalization:

  * Previous diagnosis of resistant hypertension (or current use of 3 or more maximally dosed antihypertensive agents without achievement of blood pressure control)
  * Steroid dependent asthma or emphysema
  * Cirrhosis or hepatic failure
  * Chronic heart failure (any stage)
  * Previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease
  * Previous diagnosis of cerebrovascular disease (including transient ischemic attack or stroke)
  * Known valvular heart disease
  * Stage IV or V chronic kidney disease
  * Cancer (terminal or undergoing active chemotherapeutic or radiation therapy)
* Patients with other serious medical conditions that may affect their ability to self-monitor blood pressure (such a dementia)
* Having a history of alcohol or drug abuse as determined by the CAGE-AID questionnaire (excluded if 2 or more)
* Week 2 measurement of systolic blood pressure \< 130 mm Hg using the BpTRU device or study-issued BP cuff.
Factors Influencing Bone Block Allograft Resorption

A main drawback of bone block graft surgery is the resorption occurring in early stages of healing. The aim of this work was investigate different factors associated with graft resorption in allogeneic bone block graft surgery.

Introduction: A main drawback of bone block graft surgery is the resorption occurring in early stages of healing. The aim of this work was investigate different factors associated with graft resorption in allogeneic bone block graft surgery.

Materials and methods: Twenty-eight patients referred for implant placement and with insufficient bucco-lingual (BL) alveolar bone width (\<4 mm) were included in the study. Patients received freeze dried bone allograft (FDBA) blocks of either allogeneic cancellous or cortico-cancellous bone obtained from the iliac crest. The aforementioned groups were compared in regards to bone resorption using General Estimating Equations (GEE) and logistic regression. Demographic data, trabecular bone density, graft site were also analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Twenty eight totally and partially edentulous patients referred for dental implant therapy from January 2011 to September 2015 were enrolled in the study. All patients had insufficient bucco-lingual (BL) alveolar bone width (\<4 mm) that prevented placement of regular size implants

Exclusion Criteria:

* Patients with severe systemic disease (American Society of Anesthesiology III or IV) were excluded from the study. In addition, patients who were pregnant, or patients with diseases affecting bone, such as Paget's disease, osteomalacia, diabetes, vitamin D deficiency, alcoholism, hyperthyroidism cancer or osteoporosis as well as those on medications that might affect bone metabolism, such as bisphosphonates, corticosteroids or antiepileptic medicaments were also excluded from the study.